The Zhitong Finance App learned that US pharmaceutical giant Rob Davis, CEO of MRK.US (MRK.US), said in an interview with the media on Tuesday that the future growth prospects of the pharmaceutical giant are no longer solely dependent on the major cancer treatment Keytruda. As “Medicine King” Keytruda expires in 2028, MSD management expects to launch more than 20 new products over the next five years and hedge the Keytruda patent cliff with new growth opportunities of about $70 billion in the mid-2030s.

The Zhitong Finance App learned that US pharmaceutical giant Rob Davis, CEO of MRK.US (MRK.US), said in an interview with the media on Tuesday that the future growth prospects of the pharmaceutical giant are no longer solely dependent on the major cancer treatment Keytruda. As “Medicine King” Keytruda expires in 2028, MSD management expects to launch more than 20 new products over the next five years and hedge the Keytruda patent cliff with new growth opportunities of about $70 billion in the mid-2030s.